“…Late-stage diversification strategies that are based on heteroaromatic frameworks that contain multiple reactive sites are challenging and attractive for use in drug discovery [ 1 , 2 , 3 ]. Because small changes can have a huge impact on bioactive profile, this approach offers unique opportunities for the generation of new drug-like analogs of lead structures without extra synthetic steps or resorting to de novo synthesis [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ].…”